Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
6 Athira Pharma LIFT-AD topline results (press release)September 3, 2024 announcement that fosgonimeton (a distinct HGF/c-Met modulator) did not meet the primary or key secondary endpoints in the Phase 2/3 LIFT-AD Alzheimers trial
Patient-information materials should emphasize that Bi-Amino Injection is a compounded preparation that has not been reviewed by the Food and Drug Administration for safety or efficacy, and that ongoing laboratory assessment-electrolytes, acid-base status, and renal function-forms an integral part of therapy
Go to bed and wake up at the same time every day
These individuals will likely do the best with addressing the systemic causes and likely respond best to dietary changes minimizing histamine rich foods and the use of antihistamines
